Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• Morphine tolerance, a decreased response to the drug over time, is a significant clinical challenge.
• N-methyl-D-aspartate (NMDA) and cholecystokinin (CCK)-B receptors are implicated in the mechanisms of opioid tolerance and withdrawal.

Purpose of the Study:

• To investigate the roles of NMDA and CCK-B receptors in the development and reversal of morphine tolerance.
• To determine if blocking these receptors can restore morphine's antinociceptive efficacy in tolerant subjects.

Main Methods:

• Experiments were conducted using morphine-tolerant and drug-naive rats.
• Antinociceptive effects were assessed using the hot plate test.
• Rats were administered morphine alone, or in combination with CCK-B receptor antagonist CI 988 and/or NMDA receptor antagonist dextromethorphan.

Main Results:

• In morphine-tolerant rats, both CI 988 and dextromethorphan individually enhanced morphine's antinociceptive effect.
• Combined administration of CI 988 and dextromethorphan did not produce a greater effect than either agent alone in tolerant rats.
• In drug-naive rats, dextromethorphan potentiated the analgesic effects of morphine and morphine with CI 988.

Conclusions:

• The findings suggest that NMDA receptor antagonism may potentiate morphine's analgesic effect rather than reverse tolerance.
• CCK-B receptor antagonism appears to reverse morphine tolerance at doses that do not potentiate the analgesic effect.
• Distinct mechanisms may underlie tolerance reversal and analgesic potentiation involving NMDA and CCK-B receptors.